Evidence map›Paper›PMID 32211316›Full record

ArticleFrontiers in oncology2020

Fertility Outcomes and Sperm-DNA Parameters in Metastatic Melanoma Survivors Receiving Vemurafenib or Dabrafenib Therapy: Case Report.

Marco Ghezzi, Andrea Garolla, Sabina Magagna, Iva Šabovich, Massimiliano Berretta, Carlo Foresta, Luca De Toni

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Age-Associated Proteomic Changes in Human Spermatozoa.International journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Marco GhezziDepartment of Clinical and Experimental Oncology, IOV-IRCCS, Padua, Italy.
Andrea GarollaUnit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.
Sabina MagagnaUnit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.
Iva ŠabovichUnit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.
Massimiliano BerrettaDepartment of Medical Oncology, National Cancer Institute, IRCCS Aviano, Aviano, Italy.
Carlo ForestaUnit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.
Luca De ToniUnit of Andrology and Reproductive Medicine, Department of Medicine, University of Padua, Padua, Italy.
University of Padua · ITCentro di Riferimento Oncologico · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma is a frequent neoplasm in young adult males in reproductive age, 10% of them degenerating into regional and/or distant metastases (MM). The use of BRAF inhibitors (BRAFi) vemurafenib and dabrafenib is effective in MM patients harboring

Indexed as

BRAF inhibitorscryopreservationmale fertilitymetastatic melanomasperm DNA

Identifiers

PMID32211316
PMCPMC7066495
OpenAlexW3009528146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.